Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P14784 (
IL-2 receptor
)
3,849
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have used cDNAs for the human interleukin 2 (IL-2) receptor to study
IL-2 receptor
gene expression in normal activated T cells. Resting T cells do not contain detectable
IL-2 receptor
mRNA. Within 1 hr after stimulation with phytohemagglutinin (PHA), a large, presumably nuclear precursor RNA species is seen, which then gradually disappears. Mature
IL-2 receptor
mRNA forms appear within 8 hr after stimulation, reach peak levels between 8 and 24 hr, and then decline. Thus, in PHA-activated lymphocytes the rise and fall in
IL-2 receptor
mRNA levels precede by more than 24 hr the peak and decline of
IL-2 receptor
protein expression occurring at the cell surface. 4 beta-
Phorbol 12-myristate 13-acetate
(
PMA
) also stimulates
IL-2 receptor
mRNA and protein expression by T cells. Combinations of optimal concentrations of PHA and
PMA
produce an additive effect on
IL-2 receptor
mRNA levels, suggesting that PHA and
PMA
may induce
IL-2 receptor
gene expression through different, complementary mechanisms. Nuclease S1-protection assays indicate that
IL-2 receptor
mRNAs may differ in length due to the use of three different polyadenylylation signals. Further, these assays demonstrate the presence of transcripts that lack a 216-base segment within the protein-coding region and thus do not encode a functional
IL-2 receptor
. Nuclear transcription assays indicate that the increase in
IL-2 receptor
mRNA is reflected at the level of transcription. Thus,
IL-2 receptor
gene regulation controls
IL-2 receptor
expression at the cell surface and is intimately linked to the control of T-cell proliferation.
...
PMID:Interleukin 2 receptor gene expression in normal human T lymphocytes. 392 55